
Tactile Medical Launches Next-Generation AffloVest® Airway Clearance Therapy
Track TCMD's AI-powered predictions, market trends, and investment insights.
You don't hold TCMD in your mock portfolio yet.
Upgrade to see the full Evidence Stack
What Changed, Why Now, and Risk Flags — available on the Investor plan and above
Get StartedWith EPS of 0.87 and a PE ratio of 29.08, Tactile Medical appears to be modestly profitable and priced at a growth-oriented multiple, but not at a deep discount. The valuation suggests the market is already embedding expectations of continued earnings growth, leaving less margin for error. Without clear evidence of accelerating revenue or margin expansion, the risk/reward profile looks balanced rather than clearly attractive.
The stock at $25.30 is trading meaningfully above its 200-day moving average of $22.01, which is a positive long-term technical signal. A 5.6% gain over the last month suggests improving momentum and buying interest. While short-term overbought conditions (e.g., RSI) are not specified, the price action relative to the 200-day trend skews the technical picture slightly bullish.
Web traffic of roughly 113,784 monthly visitors and slow-but-positive growth across social channels indicate a stable brand presence rather than explosive demand. The 33.3% month-over-month decline in job openings (to 42) may signal more cautious hiring, which can either reflect efficiency efforts or a more conservative growth outlook. Overall, alternative data points to steady but not strongly accelerating business momentum.
Tactile Medical shows solid profitability and trades at a growth-oriented valuation, with the stock currently in a constructive uptrend above its 200-day moving average. However, alternative data and hiring trends point more to steady execution than to strong acceleration, while the current PE multiple already prices in a fair amount of optimism. Taken together, the setup appears balanced, with neither clearly compelling upside nor pronounced downside, leading to an overall neutral stance.
Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.

Tactile Medical Launches Next-Generation AffloVest® Airway Clearance Therapy


Tactile Systems Technology, Inc. (TCMD) Q1 2026 Earnings Call Transcript

Tactile Medical (TCMD) is currently trading at $25.40 on the NASDAQ, posting a modest intraday gain of +0.9% on volume of 182,878 shares. The company carries a market capitalization of $572.9 million, positioning it as a small-cap player in the medical devices space. Tactile Medical focuses on at-home treatment solutions for chronic conditions including lymphedema, chronic venous insufficiency, and pulmonary secretion disorders — a niche but clinically significant segment of the broader medtech market that benefits from an aging U.S. patient population and growing home-care adoption trends.
TrendEdge's AI model assigns TCMD a score of 6 out of 10 — a neutral-to-moderate signal indicating the stock has identifiable strengths but also meaningful uncertainties that prevent a stronger bullish reading. At this score level, the AI is likely weighing TCMD's focused product portfolio and recurring home-use device revenue against risks such as reimbursement dependency, modest trading volume, and competitive pressures in pneumatic compression and airway clearance markets. A score of 6 suggests the stock warrants attention but not aggressive positioning without further confirmation from earnings trends or volume expansion.
Investors watching TCMD in 2026 should monitor Medicare and commercial reimbursement policy shifts, which remain a primary revenue lever for Tactile Medical's home-use device business. Any expansion of the Flexitouch Plus or AffloVest product lines into new indications could serve as a meaningful upside catalyst. Conversely, pricing pressure from competitors or tighter insurance coverage criteria represent key downside risks. The relatively low daily volume of 182,878 shares also signals limited institutional conviction at current levels, making liquidity a factor to consider for position sizing.
Unlock comprehensive alternative data signals to make better investment decisions
TrendEdge provides tools and data for research and educational purposes only and does not provide investment advice or personal recommendations.
Web Traffic
128,972
Twitter Followers
2,219
Instagram Followers
2,282
YouTube Subscribers
7,980
LinkedIn Followers
41,052
Job Postings
57
LinkedIn Employees
1,090
News Mentions
0
Key Metrics